Fig. 5: 1-way sensitivity analysis curves. | Translational Psychiatry

Fig. 5: 1-way sensitivity analysis curves.

From: Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression

Fig. 5: 1-way sensitivity analysis curves.

Show minimum 1-year remission rates necessary for DBS for TRD to achieve acceptable incremental cost-effectiveness ratios (ICER) at accepted willingness-to-pay (WTP) thresholds of $50,000 (for moderate cost-effectiveness) and $100,000 (for definitive cost-effectiveness) per QALY. DBS-pc (A) requires 55% remission for moderate cost-effectiveness and 85% remission for definitive cost-effectiveness from a healthcare sector perspective (dark blue), and 35% remission for moderate cost-effectiveness and 46% remission for definitive cost-effectiveness from a societal perspective (light blue). DBS-rc (B) requires 11% remission for moderate cost-effectiveness and 19% remission for definitive cost-effectiveness from a healthcare sector perspective (dark blue), and 8% remission for moderate cost-effectiveness and 10% remission for definitive cost-effectiveness from a societal perspective (light blue).

Back to article page